Pathological N1b Node Metastasis Itself Can Be Still a Valid Prognostic Factor in PTC after High Dose RAI Therapy.
10.11106/ijt.2016.9.2.159
- Author:
Choon Young KIM
1
;
Seung Hyun SON
;
Ji Hoon JUNG
;
Chang Hee LEE
;
Ju Hye JEONG
;
Shin Young JEONG
;
Sang Woo LEE
;
Byeong Cheol AHN
;
Jaetae LEE
Author Information
1. Department of Nuclear Medicine, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Korea. jaetae@knu.ac.kr
- Publication Type:Original Article
- Keywords:
Papillary thyroid carcinoma;
Ablation success;
Recurrence;
Radioactive iodine ablation
- MeSH:
Follow-Up Studies;
Humans;
Iodine;
Lymph Nodes;
Multivariate Analysis;
Neoplasm Metastasis*;
Recurrence;
Retrospective Studies;
Risk Factors;
Thyroglobulin;
Thyroid Neoplasms
- From:International Journal of Thyroidology
2016;9(2):159-167
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND OBJECTIVES: The aim of this study was to determine whether pathologically proven central or lateral lymph node (LN) metastasis (pN1a or pN1b) could affect ablation success and recurrence after high-dose radioactive iodine (RAI) ablation. We also sought to identify the risk factors for long-term recurrence in patients with papillary thyroid carcinoma (PTC). MATERIALS AND METHODS: A total of 277 patients with pN1 disease who had undergone high-dose RAI ablation (5.55 GBq) between 2000 and 2006 were included in this retrospective study. We compared the ablation success rate and the recurrence rate between patients with pN1a and pN1b disease. Univariate and multivariate analyses were performed to identify the risk factors for recurrence. RESULTS: The median duration of follow-up was 10.2 years. The overall ablation success rate was 64%, and the ablation success rate in the pN1b group (49%) was lower than in the pN1a group (74%). The overall recurrence rate was 23%, and the recurrence rate in the pN1b group (30%) was higher than in pN1a group (18%). A higher ratio of metastatic LNs, a higher level of pre-ablation thyroglobulin, and ablation failure were significant risk factors for recurrence by multivariate analysis. CONCLUSION: Patients with pN1b disease experienced a lower ablation success rate and a higher recurrence rate than patients with pN1a disease. However, a higher ratio of metastatic LNs, a higher level of pre-ablation thyroglobulin, and ablation failure were stronger risk factors than the pathological N stage for long term recurrence in patients with node-positive PTC.
